# Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)

Source: https://onco.cc/trials/nct06502080/  
OnCo record `nct06502080` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab, pembrolizumab, sintilimab and other drugs with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC) is a phase 2, randomised interventional study registered as NCT06502080 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 128 participants, started 2024-07 and due to reach its primary completion in 2027-06-30. Interventions recorded: Consolidative radiotherapy, Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab. Conditions listed: Biliary Tract Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: RADITOP
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06502080
- Phase: 2
- Setting: Standard-of-care Systemic Therapy With or Without Consolidative Radiotherapy in Patients With Oligometastatic/Locally Advanced Unresectable Biliary Tract Cancer: an Open-label, Randomised, Controlled Study
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 128

## Sources

- ClinicalTrials.gov NCT06502080: https://clinicaltrials.gov/study/NCT06502080

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/), [Radiotherapy](https://onco.cc/terms/radiotherapy/)

---
JSON: https://onco.cc/api/v1/entities/nct06502080.json